Talseth-Palmer, Bente A., Wijnen, Juul T., Van Wezel, Tom, Vasen, Hans F. A., Scott, Rodney J., Andreassen, Eva K., Barker, Daniel, Jagmohan-Changur, Shantie, Tops, Carli M., Meldrum, Cliff, The Dutch Cancer Genetics Group, Spigelman, Allan, Hes, Frederik J.. BioMed Central; 2013. The importance of a large sample cohort for studies on modifier genes influencing disease severity in FAP patients.

Talseth-Palmer, Bente A., Wijnen, Juul T., Suchy, Janina, Kurzawski, Grzegorz, The Dutch Cancer Genetics Group,, Spigelman, Allan, Møller, Pål, Morreau, Hans M., Van Wezel, Tom, Lubinski, Jan, Vasen, Hans F. A., Scott, Rodney J., Brenne, Ingvild S., Jagmohan-Changur, Shantie, Barker, Daniel, Ashton, Katie A., Tops, Carli M., Evans, Tiffany-Jane, McPhillips, Mary, Groombridge, Claire. John Wiley & Sons; 2013. Combined analysis of three lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers.

Talseth-Palmer, Bente A., Scott, Rodney J., Vasen, Hans F. A., Wijnen, Juul T.. Nature Publishing Group; 2012. 8q23.3 and 11q23.1 as modifying loci influencing the risk for CRC in Lynch syndrome.

Burn, John, Bishop, Timothy, Bertario, Lucio, Jarvinen, Heikki J., Lindblom, Annika, Evans, D. Gareth, Lubinski, Jan, Morrison, Patrick J., Ho, Judy W. C., Vasen, Hans F. A., Side, Lucy, Thomas, Huw J. W., Mecklin, Jukka-Pekka, Scott, Rodney J., Dunlop, Malcolm, Barker, Gail, Elliott, Faye, Jass, Jeremy R., Fodde, Ricardo, Lynch, Henry T., Mathers, John C., Macrae, Finlay, Moslein, Gabriela, Olschwang, Sylviane, Bisgaard, Marie-Luise, Ramesar, Raj, Eccles, Diana, Maher, Eamonn R.. Massachusetts Medical Society; 2008. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.

Wiik, Mariann Unhjem, Evans, Tiffany-Jane, Belhadj, Sami, Bolton, Katherine A., Dymerska, Dagmara, Jagmohan-Changur, Shantie, Capellá, Gabriel, Kurzawski, Grzegorz, Wijnen, Juul T., Valle, Laura, Vasen, Hans F. A., Lubinski, Jan, Scott, Rodney J., Talseth-Palmer, Bente A.. Nature Publishing Group; 2021. A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants.